MLYS
HealthcareMineralys Therapeutics, Inc. · Biotechnology · $2B
What is Mineralys Therapeutics, Inc.?
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension and related cardiovascular conditions. Headquartered in Radnor, Pennsylvania, the company is built around a single lead drug candidate targeting a specific hormonal pathway linked to difficult-to-control blood pressure.
Mineralys generates no product revenue yet — its business model centers on advancing lorundrostat through clinical trials toward regulatory approval. Lorundrostat is an orally administered aldosterone synthase inhibitor designed to address uncontrolled and resistant hypertension, a condition where standard treatments fall short. The company funds operations through capital raises rather than product sales, which is typical for clinical-stage biotechs at this stage of development.
Mineralys Therapeutics was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
- Lorundrostat — oral aldosterone synthase inhibitor for resistant hypertension
- Clinical-stage pipeline targeting cardiovascular disease
- Proprietary selective inhibitor mechanism with differentiated approach
Is MLYS a Good Stock to Buy?
UQS Score rates MLYS as Poor overall, reflecting the early-stage nature and inherent uncertainties of a pre-revenue biopharmaceutical company.
The Risk pillar stands out as the relative bright spot in the MLYS profile — suggesting the company's financial structure carries a degree of stability compared to what might be expected at this stage. This is not uncommon for clinical-stage biotechs that have raised sufficient runway capital.
Quality, Moat, Growth, and Valuation all register as weak or elevated, reflecting the absence of revenue, an unproven commercial moat, and a valuation that appears stretched relative to current fundamentals.
See the full pillar breakdown and detailed financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does MLYS pay dividends?
No — Mineralys Therapeutics, Inc. does not currently pay a dividend.
MLYS does not pay a dividend, which is standard for clinical-stage biopharmaceutical companies. Available capital is directed toward clinical trials, regulatory activities, and pipeline development rather than shareholder distributions. Income-focused investors should look elsewhere; MLYS is oriented entirely toward potential long-term capital appreciation tied to pipeline success.
When does MLYS report earnings?
Mineralys Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue company, quarterly reports focus primarily on cash runway, operating expenses, and clinical trial progress rather than traditional revenue or profit metrics. Pipeline milestones and trial readouts tend to move the stock more than earnings figures alone.
For the most recent quarter's results and clinical updates, visit Mineralys Therapeutics' investor relations page directly.
MLYS Price History
+61.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Mineralys Therapeutics, Inc.?
Based on Mineralys Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
MLYS Long-term Outlook
The fundamental outlook for MLYS is binary in nature — heavily dependent on clinical trial outcomes for lorundrostat. The Growth pillar registers as Weak, reflecting the absence of near-term revenue visibility. The Risk pillar offers some reassurance around financial stability, but the Valuation pillar reading of Elevated suggests the market has already priced in meaningful optimism about pipeline success.
Growth drivers
- Potential regulatory approval of lorundrostat for resistant hypertension
- Large addressable patient population with unmet treatment needs
- Possible partnership or licensing deals as clinical data matures
Key risks
- Clinical trial failure or unfavorable efficacy data for lorundrostat
- Elevated valuation leaves little margin of safety if milestones slip
- Ongoing cash burn with no product revenue to offset operating costs
MLYS vs Peers
MLYS operates in a competitive clinical-stage biotech landscape alongside other pre-revenue or early-commercial companies pursuing specialized therapeutic areas.
Agios focuses on cancer metabolism and rare blood disorders, giving it a different therapeutic focus and a more advanced commercial presence than MLYS.
Zymeworks develops bispecific antibody-based oncology therapies, representing a distinct modality and disease area compared to Mineralys's cardiovascular focus.
BioCryst has an approved rare disease product on the market, placing it further along the commercialization curve than the clinical-stage MLYS.
Frequently Asked Questions
What does Mineralys Therapeutics do?
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing lorundrostat, an oral drug candidate designed to treat uncontrolled and resistant hypertension by selectively inhibiting aldosterone synthase — a key enzyme in the hormonal pathway that drives elevated blood pressure in certain patients.
Does MLYS pay dividends?
No, MLYS does not pay a dividend. Clinical-stage biotechs like Mineralys typically reinvest all available capital into research, clinical trials, and regulatory activities. Dividend payments are not expected until the company reaches profitability, which depends on successful drug development.
When does MLYS report earnings?
Mineralys Therapeutics follows a standard quarterly reporting schedule for US-listed companies. Because it is pre-revenue, reports center on cash position and trial updates rather than traditional earnings. Check the company's investor relations page for the latest schedule and filings.
Is MLYS a good stock to buy?
UQS Score rates MLYS as Poor overall. The profile reflects weak Quality, Moat, and Growth readings alongside an Elevated Valuation — typical challenges for a pre-revenue clinical-stage biotech. The Risk pillar is the relative standout. Investors should weigh pipeline risk carefully before making any decision.
Is MLYS overvalued?
The UQS Valuation pillar for MLYS is rated Elevated, suggesting the current market price reflects significant optimism about lorundrostat's clinical and commercial potential. For a company with no product revenue, valuation is inherently speculative and tied to binary clinical outcomes.
How does MLYS compare to its competitors?
Compared to peers like BioCryst — which has an approved product — and Agios, which has a more advanced pipeline, MLYS is at an earlier stage with a single lead candidate. Its cardiovascular focus is also distinct from the oncology or rare disease areas that many clinical-stage peers pursue.
What is MLYS's market cap bracket?
MLYS is classified as a mid-cap stock. This places it in a range where institutional interest is possible, but the company still carries the concentrated pipeline risk typical of clinical-stage biotechs without diversified revenue streams.
Who founded Mineralys Therapeutics?
Mineralys Therapeutics was incorporated in 2019. Founding and leadership details are publicly available through the company's SEC filings and investor relations materials, which provide the most accurate and up-to-date information on its executive history.
Is MLYS a long-term quality investment?
As a long-term quality indicator, the UQS Score rates MLYS as Poor. Weak readings across Quality, Moat, and Growth pillars reflect the pre-revenue stage and single-asset risk. Long-term quality typically requires demonstrated earnings power and competitive durability — neither of which MLYS has established yet.
What is the main competitive advantage of Mineralys Therapeutics?
Mineralys's potential advantage lies in lorundrostat's highly selective mechanism — targeting aldosterone synthase specifically rather than broader pathways. If clinical data confirms efficacy and tolerability in resistant hypertension, that selectivity could differentiate it from existing treatment options in a large patient population.
What sector does MLYS belong to?
MLYS operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. Its focus on cardiovascular disease — particularly hypertension — places it in a therapeutic area with significant unmet need and established commercial precedent if regulatory approval is achieved.
Is MLYS a growth stock or value stock?
Based on UQS pillar labels, MLYS does not fit neatly into either category. The Growth pillar is rated Weak due to the absence of revenue, while the Valuation pillar is Elevated — meaning investors are paying a premium for future potential rather than current fundamentals. It is best characterized as a speculative pipeline play.
Unlock Full MLYS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare MLYS against clinical-stage biotech peers
- ✓Track pipeline risk signals across the Risk pillar
- ✓Get the full analyst-grade view available to Pro members
Pro Analysis
MLYS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 8, 2026 | 16.8 | 0.0 | 11.0 | 18.5 | 69.0 | 0.0 | +0.5 |
| Apr 22, 2026 | 16.3 | 0.0 | 11.0 | 18.5 | 65.5 | 0.0 | -0.9 |
| Apr 2, 2026 | 17.2 | 0.0 | 11.0 | 23.1 | 65.5 | 0.0 | — |
MLYS — Pillar Breakdown
Quality
— 0.0/100 (25%)Mineralys Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 18.5/100 (20%)Mineralys Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 69.0/100 (15%)Mineralys Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Mineralys Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)Mineralys Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for MLYS.
Score Composition
Financial Data
More Stock Analysis
How is the MLYS UQS Score Calculated?
The UQS (Unified Quality Score) for Mineralys Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Mineralys Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Mineralys Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.